Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | MPO | P05164 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | APAF1 | O14727 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 3/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.68 |
| ▸ | HTR7 | P34969 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Tryptophan SCHEMBL289042 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL475349 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL289043 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL7327 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL4732053 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL23141133 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL1120026 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL4732052 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL19161120 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL30343446 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260034-B9 | PROCESS FOR THE PREPARATION OF 2,3,4,9-TETRAHYDRO-1H-BETA-CARBOLIN-3-CARBOXYLIC ACID ESTERS | ENDURA SPA (IT) | 2012-11-07 | — | — | EP | claimed |
| EP-2260034-B1 | PROCESS FOR THE PREPARATION OF 2,3,4,9-TETRAHYDRO-1H-BETA-CARBOLIN-3-CARBOXYLIC ACID ESTERS | ENDURA SPA (IT) | 2012-02-01 | — | — | EP | claimed |
| EP-1546149-B1 | MODIFIED PICTET-SPENGLER REACTION AND PRODUCTS PREPARED THEREFROM | LILLY ICOS LLC (US) | 2008-11-26 | — | — | EP | claimed |
| EP-4333860-A1 | SERUM METABOLOMICS RELATED TO CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY | Board of Regents, The University of Texas System (US) | 2024-03-13 | — | — | EP | disclosed |
| US-9445606-B2 | Use of 4-hydroxydihydrochalcones and their salts for enhancing an impression of sweetness | SYMRISE AG (DE) | 2016-09-20 | — | — | US | disclosed |
| EP-2624829-B1 | USE OF INHIBITORS OF PORPHOBILINOGEN DEAMINASE IN THE TREATMENT OF CONGENITAL ERYTHROPOIETIC PORPHYRIA | ASOCIACIÓN CT DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE (ES) | 2015-01-21 | — | — | EP | disclosed |
| US-20100233102-A1 | USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS | SYMRISE GMBH & CO. KG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-6015698-A | CONTACTING MIXTURE OF ENANTIOMERS OF AN AMINO ACID WITH A MICROORGANISM WHICH SELECTIVELY DEGRADES THE L-AMINO ACID TO PRODUCE THE AMINE, THEN RECOVERING THE D-AMINO ACID; EFFICIENT PROCESS FOR THE INDUSTRIAL PRODUCTION OF DRUGS | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233102-A1 | USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS | TAS2R4, TAS2R1, TAS2R20 | KMT2A 1660/4885KDM4E 1138/4885MAPT 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.